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Abstract
Objectives: Previous population-based studies in patients with ulcerative colitis [UC] revealed 
variable colectomy rates and colectomy-associated risk factors. Over the past two decades, a 
decrease in colectomy rates was observed. We assessed risk factors and colectomy rates over time 
in UC in the Swiss Inflammatory Bowel Disease Cohort Study [SIBDCS].
Methods: Prospectively collected SIBDCS data, including disease history, baseline characteristics 
at enrolment, and course of disease, were retrospectively analysed. Cumulative and adjusted 
annual colectomy rates were calculated.
Results: Among 1245 UC patients analysed [54.6% male], 114 [9.2%] underwent colectomy. We 
observed 5-, 10-, 15-, and 20-year cumulative colectomy rates after diagnosis of 4.1%, 6.4%, 
10.4%, and 14.4% of patients, respectively. Male sex (odds ratio [OR] 1.54; p = 0.035), pancolitis at 
diagnosis [OR = 2.16; p = 0.005], younger age at diagnosis [OR 0.89 per 5 years of age; p = 0.006] 
and presence of extraintestinal manifestations [EIM] [OR 2.30; p  <  0.001] were risk factors for 
undergoing colectomy. We did not observe a significant protective effect of smoking on colectomy 
risk [OR 0.64; p = 0.106]. The majority of colectomies were performed within first 10 years of disease 
onset, with a rapidly decreasing colectomy rate after 15 years. In patients diagnosed after 2003, 
colectomy was performed much earlier during and individual’s disease course. Nevertheless, we 
found a significantly decreasing trend in yearly colectomy rates over time after 2005.
Conclusions: Crude and adjusted colectomy rates in Swiss UC patients were lower than those 
reported previously in the literature, and decreased over time.
Key Words:  Ulcerative colitis; colectomy rates; risk factors; cohort study
1. Introduction
UC refers to a chronic inflammatory condition of yet insufficiently 
understood aetiology, affecting the mucosal layer of the colon. 
Colectomy, hospitalisation due to severe flares, and colorectal cancer 
are amongst the most important adverse outcomes in patients with 
UC.1–5 Main indications for colectomy in UC patients can typically 
be distinguished into emergent colectomy, with fulminant or refrac-
tory colitis, and subacute to chronic complications constituting indi-
cation for surgery in the setting of elective colectomy, with colonic 
dysplasia or cancer and intolerance to medical treatment as the main 
underlying indications necessitating surgery.6,7
In previous studies, rates of colectomy in UC patients were 
revealed to be highly variable over time and geographical location. 
In a retrospective population-based series from Sweden in 1990, 
high cumulative colectomy rates of 20% after 5 years, 28% after 
10 years, and 45% after 25 years were described.8 Similar results 
were reported in a Danish cohort from Copenhagen in 1994, 
with 24% of UC patients undergoing colectomy 10  years after 
diagnosis.9 More recent studies, however, revealed considerably 
lower colectomy rates. The European Collaborative Study Group 
of Inflammatory Bowel Disease [EC-IBD] reported a cumulative 
10-year colectomy rate of 8.7%. Intriguingly, a substantial differ-
ence in colectomy rates was discovered in northern [10.4%] as
compared with southern European centres [3.9%].10 Investigations
by the Inflammatory Bowel South-Eastern Norway [IBSEN] Study
Group determined a 1-year colectomy rate of 4%.11 After 5 years,
7.5% of patients underwent colectomy; the majority among them
[almost three out of four; 71%] within the first 2 years following
diagnosis.12 After 10 years of follow-up, the cumulative colectomy
rate was 9.8% in this cohort.13 Similarly, a Canadian population-
based study revealed 5-, 10-, and 20-year overall colectomy rates
of 7.5%, 10.4%, and 14.8%, respectively.14 In addition, research-
ers from the Mount Sinai Ulcerative Colitis Surveillance Database,
including 561 patients, identified a colectomy rate of 17.3% over a 
median follow-up of 21.4 years.2
These considerably lower colectomy rates compared with the 
Scandinavian population-based studies8,9 are most likely due to a 
multitude of reasons, including variations in diagnostic accuracy 
and referral bias, as well as substantial improvements in therapeutic 
opportunities over time. Regarding the latter, Kaplan et al. described 
steadily decreasing elective but stable emergent colectomy rates 
between 1997 to 2009, possibly due to an increase in use of immu-
nomodulators and anti-tumour necrosis factor [TNF].7 In contrast, 
Jess et al. observed no significant change in surgery rates in Denmark 
from 1962 to 2005 in UC patients, reporting a fairly stable long-
term prognosis over the past five decades.15
Several risk factors have been associated with future need of 
colectomy. For instance, tobacco smoking has been described to 
exert a protective effect, with smokers being less likely to develop UC 
compared with non-smokers.16–18 Further, several studies indicated 
active smoking to be associated with milder course of UC, including 
lower colectomy rates in some19,20 but not all21 studies. Numerous 
studies identified male sex13,14,22,23 and disease extent at diagnosis 
as major risk factors.7–12 Patients with extensive colitis at diagnosis 
have a higher probability of colectomy compared with patients with 
proctitis and left-sided colitis, with an increasing risk over time in 
the case of disease progression from proctitis or left-sided colitis to 
extensive colitis during follow-up.8,10,13
Extraintestinal manifestations [EIM] may worsen the course of 
disease and therefore be associated with higher risk for complica-
tions. For instance, the risk of developing dysplasia or colorectal 
cancer is substantially increased in UC patients with concomitant 
primary sclerosing cholangitis [PSC], consecutively affecting colec-
tomy rates.3,24
In a systematic review and meta-analysis including 71 studies, no 
difference in need for surgery was identified amongst those patients 
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with versus without family history of UC.25 Likewise, no difference 
in the course of disease, including need for surgery, was observed 
between familial and sporadic inflammatory bowel disease [IBD] 
cases in a population-based study in Norway.26
In view of the currently limited and partially conflicting avail-
able literature on this topic, we aimed to investigate the cumulative 
rates of colectomy and potential changes thereof over time, as well 
as associated risk factors in UC patients in the Swiss Inflammatory 
Bowel Disease Cohort Study [SIBDCS].
2. Material and Methods
2.1. Patients
Starting in 2006, patients with an established diagnosis of IBD from 
all regions of Switzerland were included in the nationwide Swiss 
Inflammatory Bowel Disease Cohort Study [SIBDCS]27 that is finan-
cially supported by the Swiss National Science Foundation [SNSF] 
and approved by the local ethics committees [EK-1316]. All patients 
provided written informed consent. Recruitment of patients is car-
ried out in university hospitals, large non-university hospitals and 
private practices across Switzerland.
Patients with Crohn’s disease [CD], UC or colitis unclassified [CU] 
are included in the cohort if diagnosis was established at least 4 months 
before inclusion. At the time of inclusion, data acquisition focuses on 
clinical, socioeconomic, and psychosocial data. Patients then undergo 
a thorough clinical and laboratory assessment. Treating IBD physi-
cians complete detailed questionnaires focusing on physician-reported 
outcomes, whereas patient-reported outcome questionnaires evaluate 
quality of life, social impairment, and symptoms. Follow-up occurs 
once a year and additionally in case of unscheduled events.
All patients within the SIBDCS with a diagnosis of UC estab-
lished by a gastroenterologist [including patients having received 
their diagnosis of UC or having undergone colectomy before the ini-
tiation of the SIBDCS] were included in our analysis. We conducted 
an analysis of the prospectively collected data during SIBDCS fol-
low-up, including disease history characteristics at enrolment in the 
cohort. Colectomy rates and time of diagnosis in SIBDCS patients 
before inclusion in the cohort could be assessed through enrolment 
and follow-up questionnaire data.27
Non-smokers were defined as patients who had never smoked, 
either at diagnosis or during course of disease and follow-up in the 
SIBDCS; whereas ongoing smokers were defined as either patients 
who had been smoking at diagnosis of their UC and at least for 
one consecutive follow-up visit, or as patients not smoking at diag-
nosis but reporting smoking during follow-up at least once in the 
annual patient questionnaire. Smoking status is assessed at inclusion 
and also longitudinally in the annual patient as well as physician 
questionnaires of the SIBDCS. As smoking status enquired by the 
physician may be under-reported, we considered self-reporting in the 
patient questionnaire for our analysis.
2.2. Statistical analysis
Statistical analyses were carried out using the STATA software [v. 
14.2, StataCorp, College Station, TX, USA] and the R software [v 
3.23, R Foundation for Statistical Computing, Vienna, Austria].
Continuous data distribution was assessed using Normal QQ-plots. 
Normally-distributed continuous variables were summarised as mean, 
standard deviation, and range. Non-Gaussian data were summarised 
as median, interquartile range [IQR], and range. Differences in means 
between two groups for normally distributed data were assessed using 
Student’s t-test, and differences in distribution for non-Normally 
distributed data were assessed using the Mann-Whitney Wilcoxon 
rank sum test. In case of more than two groups, analysis of variance 
[ANOVA], [respectively Kruskall-Wallis test], has been used.
Categorical data were summarised as raw frequencies and rela-
tive percentages. Differences in categorical data distribution between 
two or several groups have been assessed using the chi square test, or 
Fisher’s exact test in case of insufficient sample size.
Cumulative rates of colectomy were analysed using survival ana-
lysis, including specific techniques to deal with left- and interval-
censored data. Kaplan-Meier curves were computed to analyse time 
to first occurrence of colectomy and to derive, for example, 10-year 
colectomy rates of complications, with 95% confidence intervals 
[CI]. The log-rank test was used to compare several survival curves, 
according to the different risk factors.
Multivariate logistic regression was used to assess association 
between colectomy rates and different risk factors. Crude yearly 
colectomy rates were computed with 95% confidence intervals. 
Adjusted yearly rates of colectomy were computed using multilevel 
mixed-effects logistic regression, by forcing a linear effect of calen-
dar year on the logistic level. Adjustment has been made according 
to different risk factors.
3. Results
3.1. Baseline characteristics of patients and overall 
colectomy rates
We included a total of 1245 SIBDCS patients [680 male, 54.6%] 
with UC in our analysis, with a median disease duration of 11 years 
and median age at diagnosis of 31 years. Out of these 1245 patients, 
114 underwent colectomy, with an overall 5-, 10-, 15-, and 20-year 
cumulative colectomy rate after diagnosis of 4.1% [CI: 3.09-5.41%], 
6.3% [CI: 5.00-8.00%], 10.5% [CI: 8.55-12.95%], and 14.8% [CI: 
12.06-18.02%], respectively. The majority of colectomies [73.7%, 
84 out of 114] were performed after inclusion in the SIBDCS. The 
indication for colectomy was refractory disease in the vast majority 
of cases, with colorectal cancer [4.8%] and dysplasia [7.1%] in the 
remaining cases [Tables 1, 2]. At diagnosis 37.5% of our patients 
had pancolitis [E3], 32.1% left-sided UC [E2], and 20.4% ulcera-
tive proctitis [E1] at diagnosis according to the Montreal classifi-
cation28; whereas at the last assessment before colectomy including 
84 patients who received colectomy during follow-up, 46.4% had 
pancolitis [E3], 29.8% left-sided UC [E2], and 5.9% ulcerative proc-
titis [E1]. For the remaining 30 patients the last assessment before 
colectomy was not available, due to the fact that they underwent 
colectomy before inclusion in the cohort.
Colectomised patients [114] had an extensive medical history of 
treatment with thiopurines [74.5%], any anti-TNF [48.2%], metho-
trexate [21.1%], cyclosporine [29.8%], and tacrolimus [14%].
3.2. Risk factors for colectomy
In a univariate analysis, we found male sex to be significantly asso-
ciated with colectomy, with almost two-thirds of patients [64%] 
undergoing colectomy being male [female: OR = 0.65; p = 0.035]. 
Pancolitis at diagnosis was also a highly significant risk factor for 
colectomy, with a more than 20% higher proportion of patients 
with pancolitis among those UC patients undergoing colectomy as 
compared with their counterparts without colectomy during follow-
up in the SIBDCS [left-sided colitis: OR 0.39; p < 0.002; proctitis: 
OR 0.25; p < 0.001]. Furthermore, we found younger age at diag-
nosis to be associated with higher colectomy rates [OR = 0.89 per 
5 years of age; p = 0.006]. In addition, there was a non-significant 
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association of positive family history of IBD with higher colectomy 
rates [OR = 1.69; p = 0.060; Tables 1 and 2].
In multivariate analyses, pancolitis at diagnosis [OR  =  2.16; 
p = 0.005] and disease duration [OR = 1.04; p = 0.001] were revealed 
to be independently associated with colectomy, whereas sex or age at 
diagnosis were not [Table 2]. A statistically significant linear dimin-
ishing trend with year on the logistic level for colectomy rates was 
found (beta coefficient = -0.210 [-0.323–-0.097]; p < 0.001) when 
adjusting for gender, age at diagnosis, disease duration, and previous 
use of anti-TNF agent.
3.2.1. EIM and colectomy
We found a significantly higher fraction of patients suffering from 
concomitant extraintestinal manifestations [EIM] at any time in their 
entire history of disease, with 59.6% in patients with as compared 
with 39.1% in those without colectomy [OR = 2.30; p < 0.001]. This 
increase in risk was observed for EIM overall and several individual 
EIM [Table 1].
3.2.2. Smoking and colectomy
At the last assessment before colectomy, 89.3% of the patients were 
non-smokers [Table 3]. Smoking did not have a significant protect-
ive effect on the risk of colectomy overall in the SIBDC; however, a 
potential protection might have occurred in smoking male patients 
[OR = 0.64; p = 0.106]. Likewise, considering only the most recent 
smoking status [i.e. at latest follow-up or at follow-up preceding sur-
gery] we did not observe any significant protective effects in the whole 
study population, nor in the subgroups of male or female patients.
Table 1. Baseline patient characteristics.
No colectomy Colectomy All ulcerative colitis patients p-Value
Number of patients 1131 [90.8] 114 [9.2] 1245 [100.0] -
Gender
 Male 607 [53.7] 73 [64.0] 680 [54.6]
 Female 524 [46.3] 41 [36.0] 565 [45.4] 0.034
Age at diagnosis [y]
[median, IQR, range]
31, 24 to 41
3 to 83
28, 23 to 35
11 to 75
31, 23 to 41
3 to 83
0.006
Age at enrollment [y]
[median, IQR, range]
41, 31 to 52
16 to 85
39, 31 to 50
18 to 76
41, 31 to 52
16 to 85
0.344
Age at latest follow-up [y]
[median, IQR, range]
46, 36 to 57
17 to 89
46, 37 to 57
22 to 82
46, 36 to 57
17 to 89
0.848
Disease duration [y]
[median, IQR, range]
11, 6 to 18
0 to 50
15, 9 to 22
2 to 44
11, 6 to 18
0 to 50
<0.001
Body mass index [kg/m2]
[median, IQR, range]
23.7, 21.5 to 26.4
15.1 to 62.5
23.4, 20.8 to 26.4
16.0 to 48.8
23.6, 21.5 to 26.4
15.1 to 62.5
0.392
Family history of inflammatory bowel disease
 None 885 [78.3] 90 [79.0] 975 [78.3]
 Yes 112 [9.9] 19 [16.7] 131 [10.5]
 Unknown 134 [11.8] 5 [4.4] 139 [11.2] 0.008
Disease location at diagnosis
 Pancolitis 402 [35.5] 65 [57.0] 467 [37.5]
Left-sided colitis 375 [33.2] 24 [21.1] 399 [32.1]
 Proctitis 244 [21.6] 10 [8.8] 254 [20.4]
 Unknown/unclear 110 [9.7] 15 [13.2] 125 [10.0] <0.001
History of extraintestinal manifestation ever in course of disease
 None 689 [60.9] 46 [40.4] 735 [59.0]
 Yes 442 [39.1] 68 [59.6] 510 [41.0] <0.001
 Arthralgia 362 [32.0] 52 [45.6] 414 [33.3] 0.003
 Uveitis/iritis 64 [5.7] 11 [9.6] 75 [6.0] 0.088
Pyoderma gangrenosum 18 [1.6] 4 [3.5] 22 [1.8] 0.135
Erythema nodosum 37 [3.3] 8 [7.0] 45 [3.6] 0.041
Aphtous/oral ulcers 56 [5.0] 6 [5.2] 62 [5.0] 0.884
Ankylosing spondylitis 35 [3.1] 6 [5.2] 41 [3.3] 0.216
Primary sclerosing cholangitis 33 [2.9] 18 [15.8] 51 [4.1] <0.001
History of treatment [‘ever treated with’]
5-aminosalicylic acid 1086 [96.0] 103 [90.4] 1189 [95.5] 0.005
Steroids 884 [78.2] 105 [92.1] 989 [79.4] <0.001
Thiopurines 649 [57.4] 85 [74.5] 734 [59.0] <0.001
Methotrexate 87 [7.7] 24 [21.1] 111 [8.9] <0.001
Infliximab 330 [29.2] 51 [44.7] 381 [30.6] 0.001
Adalimumab 91 [8.0] 16 [14.0] 107 [8.6] 0.030
Certolizumab 4 [0.4] 4 [3.5] 8 [0.6] 0.003
Any anti-tumour necrosis factor 352 [31.1] 55 [48.2] 407 [32.7] <0.001
Cyclosporine 63 [5.6] 34 [29.8] 97 [7.8] <0.001
Tacrolimus 38 [3.4] 16 [14.0] 54 [4.3] <0.001
IQR, interquartile range; y, years.
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3.3. Disease duration and colectomy
Overall colectomy rates were highest in the 10–20 years following 
UC diagnosis [Table 4], and numerically the majority of colectomies 
were performed within 10  years after UC diagnosis. The highest 
fraction of patients undergoing colectomy had their diagnosis before 
1997 [Table 5].
In view of the fact that crude numbers of colectomy have to be 
interpreted with caution [increase in overall risk in patients with 
longer follow-up], we subsequently analysed our data in addition 
in a time-to-event fashion with the survival approach, revealing a 
colectomy-free survival of 0.936, 0.856, and 0.816 after 10, 20, and 
30 years of disease duration, respectively [Figure 1]. As shown by the 
smoothed hazard function [depicting the instantaneous colectomy 
risk at an exact time, conditional on survival until then], we found 
the risk of colectomy to initially increase after 10 years, reaching a 
peak after about 15 years of disease duration, and to subsequently 
decrease to considerably lower risk rates [Figure 2, Table 4].
3.4. Time trends in colectomy rates: [evolution of 
colectomy rates over time]
We observed a decrease in colectomy rates over time, with evi-
dent nominal decrease in absolute numbers of annual colectomies 
performed [as well as the incident rate of colectomy] after 2010 
Table 2. Multivariate analysis of baseline characteristics.
Univariate analysis Multivariate analysisa
OR [95% CI] p-Value OR [95% CI] p-Value
Gender [ref: male] 0.651 [0.436-0.971] 0.035
Age at diagnosis [per 5 years] 0.894 [0.825-0.968] 0.006
Age at enrollment [per 5 years] 0.961 [0.898-1.028] 0.247
Age at latest follow-up [per 5 years] 0.986 [0.923-1.053] 0.676
Disease duration [per 5 years] 1.177 [1.072-1.293] 0.001 1.223 [1.082-1.383] 0.001
Body mass index [per point] 0.990 [0.946-1.036] 0.659
Family history of inflammatory bowel disease [ref: no family history] 1.668 [0.979-2.841] 0.060
Initial ulcerative colitis location [ref: pancolitis]
Left-sided colitis 0.396 [0.243-0.645] <0.001 0.463 [0.242-0.788] 0.005
 Proctitis 0.253 [0.128-0.503] <0.001 0.334 [0.163-0.688] 0.003
Smoking status at dianosis. [ref: non-smoker] 0.643 [0.376-1.098] 0.106
History of EIM [ref: no EIM recorded] 2.304 [1.556-3.413] <0.001
Therapy history [ref: never treated]
5-amino salicylic acid 0.388 [0.195-0.773] 0.007
Steroids 3.260 [1.627-6.533] 0.001
Thiopurines 2.177 [1.405-3.372] <0.001
Methotrexate 3.200 [1.940-5.279] <0.001 2.927 [1.598-5.360] 0.001
Anti-tumour necrosis factor 2.063 [1.399-3.042] <0.001
Cyclosporine 7.205 [4.481-11.585] <0.001 9.016 [5.167-15.732] <0.001
Tacrolimus 4.696 [2.527-8.726] <0.001
OR, odds ratio; CI, confidence interval; EIM, extraintestinal manifestations.
aMultivariate analysis of baseline patient characteristics according to Table 1. *Multivariate logistic regression analysis was carried out by including all uni-
variate factors with p-value <0.200, removing non-significant factors one by one until all factors remain significant. Model consistency was then tested by rein-
troducing excluded factors one by one until final model selection.
Table 3. Details of baseline characteristics of colectomy patients.
Characteristic Number [%]
Smoking status at colectomy
 Non-smoker 75 [89.3%]
 Smoker 7 [8.3%]
 Unknown 2 [2.4%]
Disease location at colectomy
 Pancolitis 39 [46.4%]
Left-sided colitis 25 [29.8%]
 Proctitis 5 [5.9%]
 Unknown/unclear 15 [17.9%]
Complications preceding colectomy
Colorectal cancer 4 [4.8%]
 Colon dysplasia 6 [7.1%]
Therapy history preceding colectomy
5-aminosalicylic acid 76 [90.5%]
Steroids 81 [96.4%]
Thiopurines 65 [77.4%]
Methotrexate 25 [29.8%]
Infliximab 44 [52.4%]
Adalimumab 20 [23.8%]
Certolizumab 4 [4.7%]
Any anti-tumour necrosis factor 48 [57.8%]
Cyclosporine 25 [29.8%]
Tacrolimus 13 [15.5%]
Details on patients undergoing colectomy during follow-up [84 patients in 
total].
Table 4. Time trends: colectomy rates according to decades.
Disease 
duration
Person-time Number of 
colectomies
Rate of 
colectomy
95% confidence 
interval
0–10 years 9737.24 67 0.006881 0.00542-0.00874
>10–20 years 4255.19 39 0.009165 0.00669-0.01254
>20–30 years 1470.01 7 0.004762 0.00227-0.00999
>30–40 years 409.98 1 0.002439 0.00034-0.01732
Rate of colectomy according to decades, analysed patients in time and num-
bers of colectomies performed.
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[Figure 3]. In an unadjusted crude prediction [forcing linear effect 
of year on the logistic level] of yearly colectomy rates, we found a 
significantly decreasing linear trend [p = 0.037] already after 2005 
[Figure  3]. For this entire period of time, when adjusting for dis-
ease duration, age at diagnosis, gender, and previous use of anti-
TNF, a statistically highly significant linear diminishing trend with 
year on the logistic level for colectomy rates was found (beta coef-
ficient = -0.210 [-0.323–-0.097]; p < 0.001). Importantly, by far the 
lowest colectomy rates observed in our follow-up time were detected 
in the last 3 years of observation, i.e. 2013–2015. The observed sur-
vival rate without colectomy, analysed in a time-to-event fashion and 
stratified by patients diagnosed before and after 2003 [with 2003 as 
the median year of diagnosis among our cohort patients; i.e. half of 
the patients were diagnosed before and after 2003], indicated that 
colectomy was performed significantly earlier during the individual 
course of disease in recently diagnosed patients [significant differ-
ence in survival curves between patients diagnosed before and after 
2003 in log-rank test, p = 0.006]. Cumulative proportions of colec-
tomy at 2, 5, or 10 years after diagnosis were roughly twice as high 
in the more recently diagnosed subgroup of cohort patients, with 
2.50%, 5.96%, and 8.64% versus 1.09%, 2.65%, and 4.71% in 
patients diagnosed after and before 2003, respectively.
4. Discussion
In this study we investigated the risk of colectomy in a large prospect-
ive cohort of UC patients over a considerable, prospective, long-term 
follow-up with a median disease duration of 11 years [with a range 
up to 50 years, IQR 6 to 18 years]. We would like to emphasise the 
following key findings. First, we found overall colectomy rates in our 
cohort at the lower end of or even lower than those described in previ-
ous literature. Second, we identified significantly decreasing colectomy 
rates in Swiss UC patients within recent years. Third, the risk of colec-
tomy according to disease duration follows a bell-shaped curve, with 
a monotonous increase in colectomy rates during the first 15 years 
after diagnosis, followed by a subsequent decrease in colectomy risk.
The overall reduction of colectomy rates represents an encourag-
ing signal for patients with recently diagnosed UC as well as those 
with a disease duration of over 20 years.
Our results reveal considerably lower cumulative colectomy rates 
of 4.1%, 6.3%, 10.5%. and 14.8% after 5-, 10-, 15-. and 20 years, 
respectively, as compared with historical studies [20.0–23.7%, 28.0–
29.9%, and 32.4–45.0% after 10, 15, and 20 years, respectively].8,9 
In addition to that, our observed cumulative rates also appear in 
line with2,13,14 or slightly lower than those observed in more recent 
investigations [7.6% and 9.8% after 5 and 10 years,13 and 7.5%12 
and 10.4%14 after 5 and 10 years, respectively].
In terms of risk factors for colectomy, our study confirmed male 
sex13,14,22,23 [almost twice as many colectomies were performed on 
male patients], lower median age at diagnosis [in accordance with14 
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Figure  1. Survival rate of colectomy-free proportion across 30  years of 
disease duration. The observed survival rate of colectomy-free proportion 
over time according to disease duration is depicted, including numbers of 
patients at risk as illustrated in a Kaplan–Meier survival estimate and a 95% 
confidence interval [CI = confidence interval].
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Figure  2. Colectomy rate according to disease duration. The smoothed 
hazard estimate of the colectomy incidence rate according to duration of 
disease is shown with a smoothed hazard function and 95% confidence 
interval. After 15 years of disease duration, a decrease in hazard rate can be 
observed [CI = confidence interval].
Table 5. Time trends: disease duration and colectomy.
No colectomy Colectomy All ulcerative colitis patients p-Value
Number of patients 1131 [90.8] 114 [9.2] 1245 [100.0] -
Disease duration [years] 11, 6-18 15, 9-22 11, 6-18
[median, IQR, range] 0 to 50 2 to 44 0 to 50 <0.001
Diagnosis year
1996 or before 287 [25.4] 45 [39.5] 332 [26.7]
 19972003 279 [24.7] 31 [27.2] 310 [24.9]
 20042008 314 [27.8] 32 [28.1] 346 [27.8]
2009 or later 251 [22.2] 6 [5.3] 257 [20.6] <0.001
Collectomy rates according to disease duration in years [y] and year of diagnosis.
IQR, interquartile range.
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and in contrast to10 previous investigations], positive family history 
of UC [in contrast to a previous meta-analysis from 201425], and 
pancolitis [more than half of all patients undergoing colectomy suf-
fered from pancolitis at diagnosis, in line with a meta-analysis23] 
whereas higher age was protective [similar to previous studies].13,29
Our study showed individual EIM to be significantly associated 
with colectomy; in particular arthralgia was present in almost half 
of all colectomised patients. This is in line with population-based 
studies from France in children,30 adults,31 or both.32 Interestingly, in 
the the latter, EIM were a rather strong risk factor for a composite 
endpoint of complications [including use of immunosuppressants or 
biologics, or need of colectomy].
It has been repetitively described that tobacco smoking is protec-
tive against UC and associated with a milder course of disease,16–18 
but a potential protective effect on the risk of colectomy remains 
dubious and unproven.10,33,34 Likewise, our results do not support 
a negative effect of smoking cessation or non-smoking on the over-
all risk of colectomy. Our results thus provide further rationale to 
encourage smoking cessation even in severe UC cases and to ulti-
mately discard still widely prevalent concerns among both physi-
cians and patients about this step.
Regarding evolution of colectomy rates over time, our findings 
indicate a clear decrease. However, if necessary, colectomy is increas-
ingly performed early in the course of disease as reported in previous 
studies.12–14,35 Our finding of a significantly earlier performance of 
colectomy in recently diagnosed patients may point to an increased 
awareness and prompter diagnosis, as well as an increasingly early 
administration of potent and/or novel medical treatment after diag-
nosis, i.e. following a rapid step-up approach. The latter potentially 
translates into a benefit for our patients, with shorter period of time 
lost with futile medical therapies. A tendency towards a more aggres-
sive treatment approach early in the course of disease may suit as 
an explanation for both the decrease in overall rates of colectomy 
in UC patients on the one hand, and an increasingly short interval 
between diagnosis and colectomy on the other. In view of a more 
rapidly enabled treatment escalation, it may be speculated that the 
peak of colectomy risk after diagnosis [Figure  2] may occur even 
earlier after diagnosis in the future, whereas the overall risk of colec-
tomy may continuously decrease. Regarding the latter, an earlier and 
more frequent use of immunomodulators and the introduction of 
biologics has been shown to reduce the requirement for surgery in 
the long term.1
Our study has several limitations. Prospective data acquisition 
in the cohort started only in 2006, so antecedent data are retrospec-
tive. Thus, we cannot exclude a recruitment bias affecting colectomy 
rates before 2006. For instance, if patients underwent colectomy 
before prospective data acquisition, these patients might not have 
been included in the cohort at all, potentially leading to a relevant 
underestimation of the colectomy rate before 2006. Yet, in clinical 
practice in Switzerland, UC patients with a very severe disease course 
previously requiring colectomy, in most instances will remain under 
the care of a gastroenterologist with special expertise in IBD, there-
fore increasing the likelihood of SIBDCS inclusion. Moreover, the 
SIBDCS is not fully population-based, with a tendency towards a 
higher fraction of patients being treated in tertiary referral centres. 
On the other hand, 80% of admitted IBD patients were included by 
gastroenterologists working in hospitals and 20% from gastroen-
terologists in private practices. Whereas in the latter, mild-moderate 
cases presumably with intrinsically lower risk of colectomy pre-
dominate, we cannot exclude that differences in the timely initia-
tion and escalation of medical treatment may influence colectomy 
rates across treating physicians. The overall colectomy rates derived 
in our cohort may even have been overestimated as a net effect of 
the aforementioned factors, and thus may be even lower in the entire 
Swiss IBD population.
Our study also has several strengths. Our results found on a 
relatively long observational time and disease duration,with a range 
of 0–50  years. Moreover, the SIBDCS follows a rigid and well- 
structured prospective data acquisition, with yearly follow-up by 
physician- as well as patient-based data acquisition, in contrast to 
several other studies on this topic which are largely or exclusively 
based on retrospective data acquisition.
In conclusion, we identified overall colectomy rates to be lower 
than expected based on clinical experience as well as studies from 
recent decades, including virtually all those described in the more 
recent literature. Our data suggest a biphasic disease course, with an 
initial increase of colectomy rates within 10 years after diagnosis and 
subsequent decline in colectomy risk after 15 years. Colectomy risk 
was lowest 20–30 years after diagnosis. We found male sex, family 
history, pancolitis, younger age, and presence of EIM to be signifi-
cant risk factors for colectomy, whereas no clear protective effect of 
smoking was identified. Furthermore, colectomy rates significantly 
decreased in Swiss UC patients, and the overall lowest colectomy 
rates were observed in the last 3 years of observation between 2013–
2015. These findings are reassuring for UC patients and indicate an 
increase in the overall efficacy of medical treatment in recent years.
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